Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine release

Journal of Neurochemistry

Volumn 115, Issue 2, 2010, Pages 325-332

  Chu, Pei Wen ^a   Hadlock, Gregory C ^b   Vieira Brock, Paula ^b   Stout, Kristen ^b   Hanson, Glen R ^a,b   Fleckenstein, Annette E ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

D2 receptor; Dopamine; Methamphetamine; Vesicular monoamine transporter 2

Indexed keywords

DOPAMINE; ETICLOPRIDE; METHAMPHETAMINE; POTASSIUM; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BRAIN SYNAPTOSOME; CONTROLLED STUDY; CYTOPLASM VESICLE; DOPAMINE RELEASE; DOPAMINE UPTAKE; DOPAMINERGIC ACTIVITY; MALE; MEMBRANE VESICLE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; TIME;

ANIMALS; CORPUS STRIATUM; DOPAMINE; DOPAMINE ANTAGONISTS; DOPAMINE UPTAKE INHIBITORS; DRUG INTERACTIONS; MALE; METHAMPHETAMINE; POTASSIUM; RATS; RATS, SPRAGUE-DAWLEY; SALICYLAMIDES; SUBCELLULAR FRACTIONS; TIME FACTORS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 78651299826     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2010.06922.x     Document Type: Article

References (44)

1. 3]dopamine from striatal slices and synaptosomes. J. Pharmacol. Exp. Ther. 240, 177-186.
2. Bradford M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of proteindye binding. Anal. Biochem. 72, 248-254.
3. Broening H. W., Morford L. L. and Vorhees C. V. (2005) Interactions of dopamine D1 and D2 receptor antagonists with D-methamphetamine- induced hyperthermia and striatal dopamine and serotonin reductions. Synapse 56, 84-93.
4. Brown J. M., Hanson G. R. and Fleckenstein A. E. (2000) Methamphetamine rapidly decreases vesicular dopamine uptake. J. Neurochem. 74, 2221-2223.
5. Brown J. M., Riddle E. L., Sandocal V., Weston R. K., Hanson J. E., Crosby M. J., Ugarte Y. V., Gibb J. W., Hanson G. R. and Fleckenstein A. E. (2002) A single methamphetamine administration rapidly decreases vesicular dopamine uptake. J. Pharmacol. Exp. Ther. 302, 497-501.
6. Bustamante D., You Z.-B., Castel M.-N., Johansson S., Goiny M., Terenius L., Hokfelt T. and Herrera-Marschitz M. (2002) Effect of single and repeated methamphetamine treatment on neurotransmitter release in substantia nigra and neostriatum of the rat. J. Neurochem. 83, 645-654.
7. Chapin D. S., Lookingland K. J. and Moore K. E. (1986) Effects of LC mobile phase composition on retention times for biogenic amines, and their precursors and metabolites. Curr. Sep. 7, 68-70.
8. Chu P.-W., Seferian K. S., Birdsall E., Truong J. G., Riordan J. A., Metcalf C. S., Hanson G. R. and Fleckenstein A. E. (2008) Differential regional effects of methamphetamine on dopamine transport. Eur. J. Pharmacol. 590, 105-110.
9. Cubells J. F., Rayport S., Rajendran G. and Sulzer D. (1994) Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J. Neurosci. 14, 2260-2271.
10. Eyerman D. J. and Yamamoto B. K. (2007) A rapid oxidation and persistent decrease in the vesicular monoamine transporter 2 after methamphetamine. J. Neurochem. 103, 1219-1227.
11. Farnsworth S. J., Volz T. J., Hanson G. R. and Fleckenstein A. E. (2009) Cocaine alters vesicular dopamine sequestration and potassiumstimulated dopamine release: The role of D2 receptor activation. J. Pharmacol. Exp. Ther. 328, 807-812.
12. Fleckenstein A. E., Gibb J. W. and Hanson G. R. (2000) Differential effects of stimulants on monoaminergic transporters: Pharmacological consequences and implications for neurotoxicity. Eur. J. Pharmacol. 406, 1-13.
13. Fleckenstein A. E., Metzger R. R., Wilkins D. G., Gibb J. W. and Hanson G. R. (1997) Rapid and reversible effects of methamphetamine on dopamine transporters. J. Pharmacol. Exp. Ther. 282, 834-838.
14. Fleckenstein A. E., Volz T. J. and Hanson G. R. (2009) Psychostimulantinduced alterations in vesicular monoamine transporter-2 function: Neurotoxic and therapeutic implications. Neuropharmacology 56, 133-138.
15. Fumagalli F., Gainetdinov R. R., Wang Y. M., Valenzano K. J., Miller G. W. and Caron M. G. (1999) Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J. Neurosci. 19, 2424-2431.
16. Gasnier B. (2000) The loading of neurotransmitters into synaptic vesicles. Biochime 82, 327-337.
17. Gibb J. W., Hanson G. R. and Johnson M. (1994) Neurochemical mechanisms of toxicity, in Amphetamine and its Analogs (Cho A. K. and Segal D. S., eds), pp. 269-295. Academic Press, San Diego.
18. Guillot T. S., Shepherd K. R., Richardson J. R., Wang M. Z., Li Y., Emson P. C. and Miller G. W. (2008) Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis. J. Neurochem. 106, 2205-2217.
19. Hadlock G. C., Chu P.-W., Walters E. T., Hanson G. R. and Fleckenstein A. E. (2010) Methamphetamine-induced dopamine transporter complex formation and dopaminergic deficits: The role of D2 receptor activation. J. Pharmacol. Exp. Ther. (in press).
20. Hadlock G. C., Baucum A. J., II, King J. L., Horner K. A., Cook G. A., Gibb J. W., Wilkins D. G., Hanson G. R. and Fleckenstein A. E. (2009) Mechanisms underlying methamphetamine-induced dopamine transporter complex formation. J. Pharmacol. Exp. Ther. 329, 169-174.
21. 3H]-DHTB binding to VMAT-2, is compromised 24 h after methamphetamine treatment. Soc. Neurosci. Abstr. 25, 1965.
22. Hogan K. A., Staal R. G. and Sonsaalla P. K. (2000) Analysis of VMAT2 binding after methamphetamine or MPTP treatment: Disparity between homogenates and vesicle preparations. J. Neurochem. 74, 2217-2220.
23. Hotchkiss A. J., Morgan M. E. and Gibb J. W. (1979) The long-term effects of multiple doses of methamphetamine on neostriatal tryptophan hydroxylase, tyrosine hydroxylase, choline acetyltransferase, and glutamate decarboxylase activities. Life Sci. 25, 1373-1378.
24. Kogan F. J., Nichols W. K. and Gibb J. W. (1976) Influence of methamphetamine on nigral and striatal tyrosine hydroxylase activity and on striatal dopamine levels. Eur. J. Pharmacol. 36, 363-371.
25. Kokoshka J. M., Metzger R. R., Wilkins D. G., Gibb J.W., Hanson G. R. And Fleckenstein A. E. (1998) Methamphetamine treatment rapidly inhibits serotonin, but not glutamate, transporters in rat brain. Brain Res. 799, 78-83.
26. LaVoie M. J. and Hastings T. G. (1999) Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: Evidence against a role for extracellular dopamine. J. Neurosci. 19, 1484-1491.
27. Nakayama M., Koyama T. and Yamashita I. (1993) Long-lasting decrease in dopamine uptake sites following repeated administration of methamphetamine in the rat striatum. Brain Res. 601, 209-212.
28. O'Dell S. J., Weihmuller F. B. and Marshall J. F. (1993) Methamphetamin- induced dopamine overflow and injury to striatal dopamine terminals: Attenuation by dopamine D1 or D2 antagonists. J. Neurochem. 60, 1792-1799.
29. Pothos E. N., Larsen K. E., Krantz D. E., Liu Y., Haycock J. W., Setlik W., Gershon M. D., Edwards R. H. and Sulzer D. (2000) Synaptic vesicle transporter expression regulates vesicle phenotype and quantal size. J. Neurosci. 20, 7297-7306.
30. Riddle E. L., Topham M. K., Haycock J. W., Hanson G. R. and Fleckenstein A. E. (2002) Differenrial trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine. Eur. J. Pharmacol. 449, 71-74.
31. Sandoval V., Riddle E. L., Hanson G. R. and Fleckenstein A. E. (2003) Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits. J. Pharmacol. Exp. Ther. 304, 1181-1187.
32. Schmitz Y., Lee C. J., Schmauss C., Gonon F. and Sulzer D. (2001) Amphetamine distorts stimulation-dependent dopamine overflow: Effects on D2 autoreceptors, transporters, and synaptic vesicle stores. J. Neurosci. 21, 5916-5924.
33. Sonsalla P. K., Gibb J. W. and Hanson G. R. (1986) Role of D1 and D2 dopamine receptor subtypes in mediating the methamphetamineinduced changes in monoamine systems. J. Pharmacol. Exp. Ther. 238, 932-937.
34. Stokes A. H., Hastings T. G. and Vrana K. E. (1999) Cytotoxic and genotoxic potential of dopamine. J. Neurosci. Rev. 55, 659-665.
35. Sulzer D. and Pothos E. N. (2000) Regulation of quantal size by presynaptic mechanisms. Rev. Neurosci. 11, 159-212.
36. Sulzer D., Pothos E., Sung H. M., Maidment N. T., Hobel B. G. and Rayport S. (1992) Weak base model of amphetamine action. Ann. N. Y. Acad. Sci. 654, 525-528.
37. Sulzer D. and Rayport S. (1990) Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: A mechanism of action. Neuron 5, 797-808.
38. Sulzer D., Sonders M. S., Poulsen N. W. and Galli A. (2005) Mechanisms of neurotransmitter release by amphetamines: A review. Prog. Neurobiol. 75, 406-433.
39. Thomas D. M., Francescutti-Verbeem D. M. and Kuhn D. M. (2008) The newly synthesized pool of dopamine determines the severity of methamphetamine-induced neurotoxicity. J. Neurochem. 105, 605-616.
40. Volkow N. D., Chang L. and Wang G.-J. et al. (2001) Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am. J. Psych. 158, 377-382.
41. Volz T. J., Farnsworth S. J., King J. L., Riddle E. L., Hanson G. R. and Fleckenstein A. E. (2007) Methylphenidate administration alters vesicular monoamine transporter-2 function in cytoplasmic and membrane-associated vesicles. J. Pharmacol. Exp. Ther. 323, 738-745.
42. Wagner G. C., Ricaurte G. A., Seiden L. S., Schuster C. R., Miller R. J. And Westley J. (1980) Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res. 181, 151-160.
43. Wilson J. M., Kalasinsky K. S., Levey A. I., Bergeron C., Reiber G., Anthony R. M., Schmunk G. A., Shannak K., Haycock J. W. and Kish S. J. (1996) Striatal dopamine nerve terminal markers in humans, chronic methamphetamine users. Nat. Med. 2, 699-703.
44. Woolverton W. L., Ricaurte G. A., Forno L. S. and Seiden L. S. (1989) Long-term effects of chronic methamphetamine administration in rhesus monkeys. Brain Res. 486, 73-78.